Table 2.

Anticoagulant treatment at baseline and during admission for patients with AF and COVID-19. Classified as deceased and not deceased

	Deceased N = 738 (%)	Not deceased N = 1061 (%)	p
Baseline anticoagulant therapy
No treatment	140 (19.1)	252 (23.8)	<0.01
VKA	360 (49.2)	384 (36.3)	<0.01
DOAC	212 (29.0)	405 (38.3)	<0.01
Anticoagulant treatment during admission
LMWH	524 (72.1)	788 (74.6)	0.251
VKA	73 (10.1)	109 (10.4)
DOAC	50 (6.9)	200 (19)	<0.01

DOAC: direct oral anticoagulants; VKA: vitamin K antagonists; LMWH: low molecular weight heparin.